Delay in treating age-related macular degeneration in Spain is associated with progressive vision loss

Eye

Volumn 23, Issue 2, 2009, Pages 326-333

  Arias, L ^a   Armada F ^b   Donate, J ^c   Garcia Arumi J ^d   Giralt, J ^d   Pazos, B ^e   Piero A ^f   Martinez F ^g   Mondejar J J ^h   Ortega, I ^b   Zlateva, G ⁱ   Buggage, R ⁱ  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e INGO   (Spain)

^f HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^g HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^h HOSPITAL UNIVERSITARIO LA FE   (Spain)

ⁱ PFIZER INC   (United States)

Author keywords

NV AMD; Spain; Treatment delay; Visual acuity

Indexed keywords

AGED; ARTICLE; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DELAYED DIAGNOSIS; DEPRESSION; DISEASE ASSOCIATION; DISEASE REGISTRY; DISEASE SEVERITY; EMOTION; FEMALE; HEALTH CARE FACILITY; HEALTH CENTER; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; PHYSICIAN; PUBLIC HEALTH; PUBLIC HEALTH SERVICE; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; SPAIN; STATISTICAL SIGNIFICANCE; THERAPY DELAY; VISUAL ACUITY; VISUAL IMPAIRMENT; ANXIETY; CHOROIDAL NEOVASCULARIZATION; CLINICAL TRIAL; COMPLICATION; DISEASE COURSE; MACULAR DEGENERATION; MULTICENTER STUDY; PATHOPHYSIOLOGY; PSYCHOLOGY; TIME; TREATMENT OUTCOME; VERY ELDERLY; VISION DISORDERS;

AGED; AGED, 80 AND OVER; ANXIETY; CHOROIDAL NEOVASCULARIZATION; DEPRESSION; DISEASE PROGRESSION; FEMALE; HUMANS; MACULAR DEGENERATION; MALE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VISION DISORDERS; VISUAL ACUITY;

EID: 60149107965     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/sj.eye.6703053     Document Type: Article

References (23)

1. Ambati J, Ambati BK, Yoo SH, Sakurai E, Lynn BC, Kuziel WA et al. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 2003; 48: 257-293.
2. Ferris III FL. Senile macular degeneration: review of epidemiologic features. Am J Epidemiol 1983; 118: 132-151.
3. Ferris III FL, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984; 102: 1640-1642.
4. Brody BL, Gamst AC, Williams RA, Smith AR, Lau PW, Dolnak D et al. Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. Ophthalmology 2001; 108: 1893-1900.
5. DeCarlo DK, Scilley K, Wells J, Owsley C. Driving habits and health-related quality of life in patients with age-related maculopathy. Optom Vis Sci 2003; 80: 207-213.
6. Mangione CM, Gutierrez PR, Lowe G, Orav EJ, Seddon JM. Influence of age-related maculopathy on visual functioning and health-related quality of life. Am J Ophthalmol 1999; 128: 45-53.
7. Rovner BW, Casten RJ, Tasman WS. Effect of depression on vision function in age-related macular degeneration. Arch Ophthalmol 2002; 120: 1041-1044.
8. Scott IU, Feuer WJ, Jacko JA. Impact of visual function on computer task accuracy and reaction time in a cohort of patients with age-related macular degeneration. Am J Ophthalmol 2002; 133: 350-357.
9. Williams RA, Brody BL, Thomas RG, Kaplan RM, Brown SI. The psychosocial impact of macular degeneration. Arch Ophthalmol 1998; 116: 514-520.
10. Chia EM, Wang JJ, Rochtchina E, Smith W, Cumming RR, Mitchell P. Impact of bilateral visual impairment on health-related quality of life: the Blue Mountains Eye Study. Invest Ophthalmol Vis Sci 2004; 45: 71-76.
11. Gonzales CR, VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. Retina 2005; 25: 815-827.
12. Bonastre J, Le Pen C, Soubrane G, Qtel G. The burden of age-related macular degeneration: results of a cohort study in two French referral centres. Pharmacoeconomics 2003; 21: 181-190.
13. Hopley C, Salkeld G, Wang JJ, Mitchell P. Cost utility of screening and treatment for early age related macular degeneration with zinc and antioxidants. Br J Ophthalmol 2004; 88: 450-454.
14. Oliver-Fernandez A, Bakal J, Segal S, Shah GK, Dugar A, Sharma S. Progression of visual loss and time between initial assessment and treatment of wet age-related macular degeneration. Can J Ophthalmol 2005; 40: 313-319.
15. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1991; 109: 1220-1231.
16. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report no. 1. Arch Ophthalmol 1999; 117: 1329-1345.
17. Gragoudas ES, Adamis AP, Cunningham Jr ET, Feinsod M, Guyer DR, VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805-2816.
18. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, D'Amico DJ, Masonson HN, Patel M, Adamis AP, Patel M et al. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006; 113: 992-1001.
19. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, Chakravarthy U, Adamis AP, Cunningham Jr ET, Goldbaum M, Guyer DR et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 1508-1521.
20. Klaver CC, Assink JJ, van Leeuwen R, Wolfs RC, Vingerling JR, Stijnen T et al. Incidence and progression rates of age-related maculopathy: the Rotterdam Study. Invest Ophthalmol Vis Sci 2001; 42: 2237-2241.
21. Vingerling JR, Dielemans I, Hofman A, Grobbee DE, Hijmering M, Kramer CF et al. The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology 1995; 102: 205-210.
22. American Academy of Ophthalmology. Preferred Practice Pattern: Age-Related Macular Degeneration. American Academy of Ophthalmology: San Francisco, 2006, p 4.
23. Shah S, Zlateva G, Zhou S, Javitt JC. Comparison of comorbid conditions between wet AMD patients and a control cohort in the Medicare Population. Invest Ophthalmol Vis Sci 2006; 47 (E-abstract 2209).